We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

ST266 Eyedrops for the Treatment of Persistent Corneal Epithelial Defects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05066698
Recruitment Status : Terminated (Sponsor undergoing financial hardships - no longer able to support trial; no safety concerns.)
First Posted : October 4, 2021
Last Update Posted : October 25, 2022
Sponsor:
Collaborator:
IQVIA Biotech
Information provided by (Responsible Party):
Noveome Biotherapeutics, formerly Stemnion

Brief Summary:
The primary objective is to determine the efficacy of ST266 eye drops in healing persistent epithelial defects (PED). After 8 weeks of randomized, double-blind treatment, non-healers will enter into an additional 8-week open-label ST266 treatment period. All patients will be followed for 3-months post-treatment for monitoring of safety and maintenance of re-epithelialization.

Condition or disease Intervention/treatment Phase
Persistent Corneal Epithelial Defect Biological: ST266 Other: 0.67% Sodium Chloride Ophthalmic Solution Biological: Open-label ST266 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Randomized, Double-Blind, Placebo-Controlled trial with Open-Label Extension
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2b, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study With Open-Label Extension to Evaluate the Safety and Efficacy of ST266 Eye Drops in the Treatment of Persistent Corneal Epithelial Defects
Actual Study Start Date : April 27, 2022
Actual Primary Completion Date : September 7, 2022
Actual Study Completion Date : September 7, 2022

Arm Intervention/treatment
Experimental: ST266
Topical ocular application: one drop in the study eye four times a day for 8 weeks
Biological: ST266
Topical ocular application: one drop four times a day for eight weeks

Biological: Open-label ST266
Open label extension for non-healers after completion of double-blind treatment phase: topical ocular application of one drop four times a day for eight weeks

Placebo Comparator: Placebo
Topical ocular application: one drop in the study eye four times a day for 8 weeks
Other: 0.67% Sodium Chloride Ophthalmic Solution
Topical ocular application: one drop four times a day for eight weeks
Other Name: Placebo

Biological: Open-label ST266
Open label extension for non-healers after completion of double-blind treatment phase: topical ocular application of one drop four times a day for eight weeks




Primary Outcome Measures :
  1. Clinical Success [ Time Frame: 8 weeks ]
    Proportion of subjects with clinical success between ST266 and placebo arms, defined as complete re-epithelialization of the corneal epithelial defect by week 8 of treatment.


Secondary Outcome Measures :
  1. Safety of ST266 [ Time Frame: 7 months ]
    Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) in subjects treated with ST266 versus placebo

  2. Time to re-epithelialization [ Time Frame: 8 weeks ]
    Time (in days) to first complete re-epithelization of PED in subjects treated with ST266 versus placebo.

  3. Maintenance of re-epithelialization during treatment [ Time Frame: 8 weeks ]
    Time (in days) of re-epithelialization maintenance during treatment.

  4. Maintenance of re-epithelialization post-treatment [ Time Frame: 12 weeks ]
    Maintenance of corneal re-epithelization at 2 weeks and up to 12 weeks after the end of treatment in subjects treated with ST266 versus placebo.

  5. Change in BCVA from Baseline [ Time Frame: 7 months ]
    Mean change in Best Corrected Visual Acuity (BCVA) from Baseline over time and maintenance up to 12 weeks after the end of treatment in subjects treated with ST266 versus placebo.

  6. Incidence of Rescue Therapy [ Time Frame: 8 weeks ]
    Incidence of need for rescue within 8 weeks in subjects treated with ST266 versus placebo.

  7. Clinical Success in Open-Label Extension [ Time Frame: 8 weeks ]
    Proportion of subjects with complete re-epithelization of the corneal epithelial defect after 8 weeks of open label treatment based on the Independent Reading Center (IRC) image assessment.

  8. Use of Lubricating Drops [ Time Frame: 8 weeks ]
    Mean usage of preservative-free lubricating drops used for comfort in subjects treated with ST266 versus placebo.

  9. VAS Score [ Time Frame: 8 weeks ]
    Mean change in Visual Analog Scale (VAS) score from Baseline over time in subjects treated with ST266 versus placebo.

  10. Size of Defect [ Time Frame: 7 months ]
    Size of epithelial defect



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male and non-pregnant/non-breastfeeding female subjects aged 18 years and older.
  2. Subjects with a PED present for at least seven (7) days at the time of Screening.
  3. The defect must be at least 1.0 mm (longest linear measurement) at Screening and Baseline (Day 1) and must be measurable by slit lamp.
  4. In the Investigator's opinion, the defect is persistent i.e., the defect has not shown improvement despite conventional treatment such as tear supplements and bandage contact lenses.
  5. The original defect to the cornea must be the result of an injury, infection, disease, or surgery to the eye.

Exclusion Criteria:

  1. Diabetic cohort only: enrollment will be limited to include up to 50% of subjects with diabetes, as indicated by HbA1c level >6.5%. Subjects with a HbA1c level >6.5% after closure of the diabetic cohort will be excluded.
  2. Subjects currently being treated with cenegermin or other rhNGF in the study eye.
  3. Subjects currently using topical antibiotic eye drops in the study eye. Subjects on current antibiotic therapy must be willing to switch to study-provided moxifloxacin.
  4. Subjects currently taking topical steroids or corticosteroid-containing eye drops or ointment in the study eye. Subjects currently taking systemic corticosteroids with a dose of >10mg/day prednisone or equivalent.
  5. Subjects currently using topical antihistamine eye drops or vasoconstrictors in the study eye.
  6. Subjects currently using topical or local immunosuppressive agents (e.g., optic cyclosporine or lifitegrast) in the study eye.
  7. Subjects who require treatment with autologous serum eyedrops or amnion products in the study eye.
  8. Subjects who need to use contact lenses for refractive correction during the study.
  9. Subjects who require treatment with bandage contact lens or punctal plugs in the study eye that cannot be removed.
  10. Subjects currently taking antiviral medications for an active infection in the study eye. Subjects taking antiviral medications for prophylaxis may be enrolled in the study at the Investigator's discretion, provided that the subject remain on a stable dosing regimen throughout the duration of the study.
  11. History of ocular surgery (including laser or refractive surgery) in the study eye within 1 month prior to study screening or, in the opinion of the Investigator, there are persistent post-surgical complications that would impact the study data.
  12. Subjects with an uncontrolled lid or ocular infection in the study eye.
  13. History of alkali burns of the cornea.
  14. The circumference affected by limbal blood vessel ischemia is greater than 75 percent of the limbal circulation.
  15. Subjects with severe lid abnormalities contributory to the persistence of the PED such as inability to close the lids.
  16. Subjects who have a history of AIDS or HIV.
  17. Subjects who have participated in a clinical trial (including a previous study involving ST266) within 30 days prior to Day 1.
  18. Subjects who have more than one distinct PED in the study eye prior to screening visits. Subjects who develop PEDs after the screening visit will remain in the study; however, only the original study PED will be assessed.
  19. For subjects with bilateral PEDs, only the eye with the larger PED should be entered into the study. The non-study eye will receive standard of care treatment and be observed throughout the trial.
  20. Subjects with bullous keratopathy in the study eye.
  21. Subjects with corneal perforation or impending corneal perforation in the study eye.
  22. Subjects with uncontrolled glaucoma.
  23. Female subjects who are pregnant or breastfeeding. Female subjects who are neither postmenopausal for at least 1 year nor surgically sterile require a negative urine pregnancy test. All subjects must use an acceptable form of birth control during the study such as abstinence, barrier method, or hormonal contraceptive.
  24. Epithelial defect was classified as a progressive corneal melt caused by an immunological process such as rheumatoid melt or Mooren's ulceration.
  25. Subjects with recurrent corneal erosion or corneal basement membrane dystrophy.
  26. Known hypersensitivity to study provided lubricating drops, antibiotic drops, and/or procedural medications such as fluorescein dye.
  27. Consideration by the Investigator, for any reason, that the subject is an unsuitable candidate to receive ST266.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05066698


Locations
Show Show 31 study locations
Sponsors and Collaborators
Noveome Biotherapeutics, formerly Stemnion
IQVIA Biotech
Layout table for additonal information
Responsible Party: Noveome Biotherapeutics, formerly Stemnion
ClinicalTrials.gov Identifier: NCT05066698    
Other Study ID Numbers: ST266-PED-202
First Posted: October 4, 2021    Key Record Dates
Last Update Posted: October 25, 2022
Last Verified: October 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Ophthalmic Solutions
Pharmaceutical Solutions